Skip to main content
Signal8
Launch Terminal

Korsana Biosciences, Inc. (KRSA)

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. Its product pipeline includes several sGC stimulators, small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate. The company was founded on September 6, 2018 and is headquartered in Cambridge, MA.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Korsana Biosciences, Inc. logo

Korsana Biosciences, Inc.

NASDAQ:KRSAHealthcare
-6.34%$31.31
AH Close$31.31+0.00%vs close
Mkt Cap$1.43B
Float2.37M
O/S45.54M
Inst Own1.0%
SI0.5%
Dilution
Korsana Biosciences, Inc. logoNASDAQ:KRSA$31.31-6.34%
FormDescription
144
Notice of Proposed Sale of Securities
13G/A
Beneficial Ownership Report (Amended)
DEF 14A
Definitive Proxy Statement
4
13G/A
Beneficial Ownership Report (Amended)
PRE 14A
Preliminary Proxy Statement
5
144
Notice of Proposed Sale of Securities
144
Notice of Proposed Sale of Securities
13G
Beneficial Ownership Report
1
144
Notice of Proposed Sale of Securities
13G
Beneficial Ownership Report
13D
Beneficial Ownership Report (Active)
4
13D
Beneficial Ownership Report (Active)
8-K
1.01,2.01,2.02,3.02,3.03,5.01,5.02,5.03,5.05,5.06,7.01,9.01
6
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
3
Initial Statement of Beneficial Ownership
3
Initial Statement of Beneficial Ownership
3
Initial Statement of Beneficial Ownership
3
Initial Statement of Beneficial Ownership
3
Initial Statement of Beneficial Ownership
3
Initial Statement of Beneficial Ownership
3
Initial Statement of Beneficial Ownership
3
Initial Statement of Beneficial Ownership

1-25 of 389

…